<DOC>
	<DOCNO>NCT00199368</DOCNO>
	<brief_summary>This 1-year , open-label , long-term safety extension patient complete prior istradefylline study 6002-EU-007 , 6002-US-013 6002-US-018 .</brief_summary>
	<brief_title>An Extension Istradefylline Parkinson 's Disease Patients Who Have Completed Studies 6002-EU-007 , 6002-US-013 6002-US-018</brief_title>
	<detailed_description>Patients Parkinson 's disease motor complication levodopa therapy complete prior double-blind study 6002-EU-007 , 6002-US-013 6002-US-018 eligible enter 1-year , long-term open safety study start istradefylline dose 40mg per day .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Completion study 6002EU007 , 6002US013 6002US018 Nonpregnant either childbearing potential use specified contraception History psychotic illness Variant/atypical Parkinson 's disease Cancer within 5 year enrollment ALT/AST level &gt; 1.5 time ULN Seizure disorder Neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end dose wear</keyword>
	<keyword>OFF time</keyword>
</DOC>